These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1153 related articles for article (PubMed ID: 3791270)

  • 1. Clinical drug development: an analysis of phase II trials, 1970-1985.
    Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
    Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic response in phase I trials of antineoplastic agents.
    Estey E; Hoth D; Simon R; Marsoni S; Leyland-Jones B; Wittes R
    Cancer Treat Rep; 1986 Sep; 70(9):1105-15. PubMed ID: 3527410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J; Baral S; Tu D; Nomikos D; Seymour L
    Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.
    Marx KA; O'Neil P; Hoffman P; Ujwal ML
    J Chem Inf Comput Sci; 2003; 43(5):1652-67. PubMed ID: 14502500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
    Fodstad O; Aamdal S; Pihl A; Boyd MR
    Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
    Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE
    Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
    Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
    Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
    Rinehart J; Adjei AA; Lorusso PM; Waterhouse D; Hecht JR; Natale RB; Hamid O; Varterasian M; Asbury P; Kaldjian EP; Gulyas S; Mitchell DY; Herrera R; Sebolt-Leopold JS; Meyer MB
    J Clin Oncol; 2004 Nov; 22(22):4456-62. PubMed ID: 15483017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of retinol in patients with advanced cancer.
    Goodman GE
    Cancer Treat Rep; 1986 Aug; 70(8):1023-4. PubMed ID: 3731149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
    Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
    Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors.
    Miller TP; Jones SE; Chester A
    Cancer Treat Rep; 1980; 64(8-9):1001-3. PubMed ID: 7448818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targeted treatments in lung cancer--overview of clinical trials.
    Korfee S; Gauler T; Hepp R; Pöttgen C; Eberhardt W
    Lung Cancer; 2004 Aug; 45 Suppl 2():S199-208. PubMed ID: 15552800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
    Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trials in cancer: present status and analysis methods.
    Lee YJ
    Drugs Exp Clin Res; 1986; 12(1-3):57-71. PubMed ID: 3732056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
    Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
    Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
    Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
    Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.